Utilization of titanium oxide-like compound as an inorganic phosphate adsorbent for the control of serum phosphate level in chronic renal failure
Access this Article
Search this Article
Hyperphosphatemia adversely affects the prognosis of patients with chronic renalfailure (CRF). We synthesized a titanium oxide-like compound (TAP) as a phosphateadsorbent for treatment of hyperphosphatemia in CFR patients. We evaluated the abilityof TAP to adsorb inorganic phosphate in vitro and in vivo. TAP was shown to containsulfate and hydroxyl groups by thermal analysis, which probably involved in phosphateadsorption through an ionic exchange mechanism. TAP constantly adsorbed phosphate(66.20-72.84 mg/g TAP) over a wide pH range (1.22-7.27) in vitro. To evaluate the phosphatebinding potential of TAP in vivo, adenine-induced CRF rats were fed AIN-76 dietcontaining 3% TAP, 10% TAP, 3% sevelamer hydrochloride (clinical phosphate adsorbent),or 3% calcium carbonate, and serum levels of phosphate and calcium and urinary phosphatewere compared with those in untreated CRF rats. Orally administered TAP showedthe inhibitory effect on serum phosphate level in adenine-induced CRF rats, which wasequivalent to that of sevelamer hydrochloride. These results indicate that TAP is a usefulalternative phosphate-binder with fewer side effects than sevelamer hydrochlorideand calcium carbonate.
- The journal of medical investigation : JMI
The journal of medical investigation : JMI 57(3-4), 275-283, 2010-08